GTTX — GeneTether Therapeutics Share Price
Last trade - 00:00- CA$1.94m
- CA$0.22m
- 50
- 38
- 73
- 53
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.47 | ||
| Price to Tang. Book | 0.47 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -57.93% | ||
| Return on Equity | -45.02% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
GeneTether Therapeutics Inc. is a Canada-based genetic medicines company focused on creating gene editing therapies based on its proprietary GeneTether platform. The Company's platform technology uses a proprietary method to tether donor deoxyribonucleic acid (DNA) templates to the genome editing complex, making the template readily available for use during the genome editing repair stage. By positioning a donor DNA template directly at the site of a double strand break, the Company's GeneTether platform drives the DNA repair process towards homology-directed repair (HDR), a cellular repair mechanism that incorporates the genetic information of a DNA template. It is building a discovery pipeline focused on the treatment of rare, monogenic diseases of the kidney and the skin. The Company's GeneTether platform may also allow for high fidelity engineering of cells to permanently deliver the therapeutic proteins necessary to treat certain genetic diseases.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- October 13th, 2021
- Public Since
- March 28th, 2022
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Canadian Securities Exchange
- Shares in Issue
- 38,744,674
- Address
- c/o Pushor Mitchell LLP, KELOWNA, V1Y 2B3
- Web
- https://genetether.com/
- Phone
- +1 2508691195
- Auditors
- Horne LLP
Similar to GTTX
Albert Labs International
Canadian Securities Exchange
Algernon Pharmaceuticals
Canadian Securities Exchange
Alpha Cognition
Canadian Securities Exchange
Asep Medical Holdings
Canadian Securities Exchange
Awakn Life Sciences
Canadian Securities Exchange
FAQ
As of Today at 14:51 UTC, shares in GeneTether Therapeutics are trading at CA$0.02. This share price information is delayed by 15 minutes.
Shares in GeneTether Therapeutics last closed at CA$0.02 and the price had moved by over the past 365 days. In terms of relative price strength the GeneTether Therapeutics share price has underperformed the Toronto Stock Exchange 300 Composite Index by -9.91% over the past year.
There is no consensus recommendation for this security.
GeneTether Therapeutics does not currently pay a dividend.
GeneTether Therapeutics does not currently pay a dividend.
GeneTether Therapeutics does not currently pay a dividend.
To buy shares in GeneTether Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.02, shares in GeneTether Therapeutics had a market capitalisation of CA$0.77m.
Here are the trading details for GeneTether Therapeutics:
- Country of listing: Canada
- Exchange: CNX
- Ticker Symbol: GTTX
Based on an overall assessment of its quality, value and momentum GeneTether Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like GeneTether Therapeutics. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -2.5%.
As of the last closing price of CA$0.02, shares in GeneTether Therapeutics were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The GeneTether Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.02.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on GeneTether Therapeutics' directors